FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2607151714> ?p ?o ?g. }

• W2607151714 endingPage "119" @default.
• W2607151714 startingPage "113" @default.
• W2607151714 abstract "Background: Standard treatment for BCG-refractory urothelial cancer is radical cystectomy. Identification of active agents is clearly warranted. Objective: To determine a safe dose of oral everolimus in combination with standard intravesical gemcitabine and to evaluate the efficacy of this combination. Methods: Patients with carcinoma in situ refractory to intravesical bacillus Calmette-Guérin and refusing cystectomy were eligible. Patients in the phase I part of the trial received one of three dose levels of oral everolimus. Patients also received a fixed dose of intravesical gemcitabine. Maintenance everolimus was given for 12 months in patients achieving a complete response confirmed by cystoscopy and cytology. Patients in phase II received continuous everolimus administered at 10 mg daily with intravesical gemcitabine followed by everolimus maintenance for 12 months of total therapy. The enrollment goal for the phase II was 33 patients. Results: 14 patients were enrolled in phase I of the trial. 23 patients were enrolled in phase II of the trial and 19 were evaluable for primary and secondary endpoints. Four patients withdrew consent prior to treatment initiation. Of the 19 patients evaluable for response, 3 (16%, 95% confidence interval [CI] 3% - 40%) were disease free at 1 yr. The probability of RFS was 20% (95% CI 5% - 42%) at 12 months. Ten patients out of 19 had grade 3 or greater toxicity events. Seven withdrew consent or were taken off study. Conclusions: Many patients withdrew, and enrollment was halted. Continuous oral everolimus plus intravesical gemcitabine was not well tolerated in this patient population where the threshold for tolerability is low." @default.
• W2607151714 created "2017-04-28" @default.
• W2607151714 creator A5015695327 @default.
• W2607151714 creator A5035902985 @default.
• W2607151714 creator A5035907521 @default.
• W2607151714 creator A5048541532 @default.
• W2607151714 creator A5050435057 @default.
• W2607151714 creator A5052271294 @default.
• W2607151714 creator A5064884168 @default.
• W2607151714 creator A5074373241 @default.
• W2607151714 creator A5075829688 @default.
• W2607151714 creator A5082612069 @default.
• W2607151714 creator A5086957919 @default.
• W2607151714 date "2017-04-27" @default.
• W2607151714 modified "2023-09-24" @default.
• W2607151714 title "Single Arm Phase I/II Study of Everolimus and Intravesical Gemcitabine in Patients with Primary or Secondary Carcinoma In Situ of the Bladder who failed Bacillus Calmette Guerin (NCT01259063)" @default.
• W2607151714 cites W1725351598 @default.
• W2607151714 cites W1840050571 @default.
• W2607151714 cites W1931508686 @default.
• W2607151714 cites W1968048186 @default.
• W2607151714 cites W1973025363 @default.
• W2607151714 cites W1979980489 @default.
• W2607151714 cites W1983989072 @default.
• W2607151714 cites W2043283767 @default.
• W2607151714 cites W2045937905 @default.
• W2607151714 cites W2069617614 @default.
• W2607151714 cites W2075150946 @default.
• W2607151714 cites W2080770946 @default.
• W2607151714 cites W2090906593 @default.
• W2607151714 cites W2103257412 @default.
• W2607151714 cites W2118677643 @default.
• W2607151714 cites W2119010338 @default.
• W2607151714 cites W2121141015 @default.
• W2607151714 cites W2123309701 @default.
• W2607151714 cites W2128388706 @default.
• W2607151714 cites W2134253312 @default.
• W2607151714 cites W2152106693 @default.
• W2607151714 cites W2157244703 @default.
• W2607151714 cites W2162756611 @default.
• W2607151714 cites W2235523093 @default.
• W2607151714 cites W2333193688 @default.
• W2607151714 cites W2398561777 @default.
• W2607151714 cites W2409074572 @default.
• W2607151714 cites W2414199713 @default.
• W2607151714 cites W3185088747 @default.
• W2607151714 cites W41337129 @default.
• W2607151714 cites W4251083747 @default.
• W2607151714 doi "https://doi.org/10.3233/blc-170095" @default.
• W2607151714 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5409047" @default.
• W2607151714 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28516156" @default.
• W2607151714 hasPublicationYear "2017" @default.
• W2607151714 type Work @default.
• W2607151714 sameAs 2607151714 @default.
• W2607151714 citedByCount "13" @default.
• W2607151714 countsByYear W26071517142019 @default.
• W2607151714 countsByYear W26071517142020 @default.
• W2607151714 countsByYear W26071517142022 @default.
• W2607151714 countsByYear W26071517142023 @default.
• W2607151714 crossrefType "journal-article" @default.
• W2607151714 hasAuthorship W2607151714A5015695327 @default.
• W2607151714 hasAuthorship W2607151714A5035902985 @default.
• W2607151714 hasAuthorship W2607151714A5035907521 @default.
• W2607151714 hasAuthorship W2607151714A5048541532 @default.
• W2607151714 hasAuthorship W2607151714A5050435057 @default.
• W2607151714 hasAuthorship W2607151714A5052271294 @default.
• W2607151714 hasAuthorship W2607151714A5064884168 @default.
• W2607151714 hasAuthorship W2607151714A5074373241 @default.
• W2607151714 hasAuthorship W2607151714A5075829688 @default.
• W2607151714 hasAuthorship W2607151714A5082612069 @default.
• W2607151714 hasAuthorship W2607151714A5086957919 @default.
• W2607151714 hasBestOaLocation W26071517141 @default.
• W2607151714 hasConcept C121332964 @default.
• W2607151714 hasConcept C121608353 @default.
• W2607151714 hasConcept C126322002 @default.
• W2607151714 hasConcept C126894567 @default.
• W2607151714 hasConcept C141071460 @default.
• W2607151714 hasConcept C142424586 @default.
• W2607151714 hasConcept C143998085 @default.
• W2607151714 hasConcept C2775910329 @default.
• W2607151714 hasConcept C2776694085 @default.
• W2607151714 hasConcept C2777546739 @default.
• W2607151714 hasConcept C2777661416 @default.
• W2607151714 hasConcept C2778769751 @default.
• W2607151714 hasConcept C2779699572 @default.
• W2607151714 hasConcept C2780258809 @default.
• W2607151714 hasConcept C2780352672 @default.
• W2607151714 hasConcept C2908647359 @default.
• W2607151714 hasConcept C71924100 @default.
• W2607151714 hasConcept C77411442 @default.
• W2607151714 hasConcept C87355193 @default.
• W2607151714 hasConcept C99454951 @default.
• W2607151714 hasConceptScore W2607151714C121332964 @default.
• W2607151714 hasConceptScore W2607151714C121608353 @default.
• W2607151714 hasConceptScore W2607151714C126322002 @default.
• W2607151714 hasConceptScore W2607151714C126894567 @default.
• W2607151714 hasConceptScore W2607151714C141071460 @default.
• W2607151714 hasConceptScore W2607151714C142424586 @default.
• W2607151714 hasConceptScore W2607151714C143998085 @default.

• next